Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | FASN | P49327 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129558 | 0.76 | ALDH1A1 (0.44) | MGLLALDH1A1LMNAGLAHTT | |
| SCHEMBL2518614 | 0.76 | MGLL (0.77) | MGLLMEN1KMT2AHSD11B1 | |
| SCHEMBL18321690 | 0.76 | FASN (0.54) | MGLLALDH1A1HTTSMN1; SMN2FASN | |
| SCHEMBL18321692 | 0.76 | FASN (0.54) | MGLLALDH1A1HTTSMN1; SMN2FASN | |
| SCHEMBL13391197 | 0.75 | MGLL (0.65) | MGLLMEN1KMT2AHSD11B1 | |
| SCHEMBL5475136 | 0.74 | MAPT (0.52) | ALDH1A1HTTMEN1KMT2AHSD11B1 | |
| SCHEMBL5475138 | 0.74 | MAPT (0.52) | ALDH1A1HTTMEN1KMT2AHSD11B1 | |
| SCHEMBL8149182 | 0.73 | MGLL (0.67) | MGLLALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL3634776 | 0.73 | NAMPT (0.58) | ALDH1A1FASN | |
| SCHEMBL8109771 | 0.73 | KMT2A (0.69) | MGLLALDH1A1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | claimed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | claimed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | MGLL 2824/4885ALDH1A1 14/4885LMNA 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.